Sun Pharma Advanced Research Company Ltd (SPARC) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sun Pharma Advanced Research Company Ltd on NSE and BSE, with an AI summary of each filing.
Monitoring Agency Report for the quarter ended September 30, 2026
Others (Uncategorized) · 03 Nov 2026, 1:41 am
SPARC Reports Zero Deviation in Preferential Issue Utilization for Q2 FY26-27 Acuité Ratings & Research issued a clean Monitoring Agency Report for Sun Pharma Advanced Research Company Ltd. for the quarter ended 30th Sep'26, confirming zero deviation from stated objects. Out of the total ₹599.98 Cr preferential warrant issue, ₹150.00 Cr raised earlier was fully utilized toward working capital loan repayment during Q1 FY26-27. No additional warrants were subscribed or funds received during Q2 FY26-27, leaving zero additional utilization during the quarter across R&D clinical trial activities (₹300.00 Cr allocated) and general corporate purposes (₹149.98 Cr allocated).
Financial Results for the quarter and half year ended September 30, 2026
Financial Result · 03 Nov 2026, 1:35 am
Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2026.
Outcome · 03 Nov 2026, 1:16 am
Sun Pharma Advanced Research Company Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakhs) ■ Revenue: 3,003 (+282.1% YoY | -24.8% QoQ) ■ EBITDA: -4,561 (+30.6% YoY | -34.1% QoQ) ■ EBITDA Margin (%): -152 (+68425 bps YoY | -6671 bps QoQ) ■ PAT: -2,439 (+67.8% YoY | -17.4% QoQ) ■ EPS (INR): -0.75 (+67.9% YoY | -17.2% QoQ)
Sun Pharma Advanced Research Company Limited has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 02 Nov 2026, 5:30 am
To consider and approve the financial results for the quarter and half year ended September 30, 2026
Intimation · 02 Nov 2026, 5:30 am
Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve unaudited ....
Intimation · 02 Nov 2026, 5:30 am
SPARC Schedules Board Meeting on 2nd Nov'26 to Consider Q2 FY27 Results Sun Pharma Advanced Research Company Ltd (SPARC) has scheduled a Board of Directors meeting for 2nd Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for dealing in company securities has been closed for designated persons starting 1st Oct'26 and will remain closed until 48 hours after the declaration and submission of the financial results to stock exchanges.
Update on Litigation under regulation 30 of SEBI (LODR), 2015
Others (Uncategorized) · 04 Oct 2026, 6:08 pm
SPARC Secures Favourable CESTAT Ruling for Rs 27.51 Crore CENVAT Credit Refund Sun Pharma Advanced Research Company Limited (SPARC) received a favourable ruling from the Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Mumbai. The Tribunal dismissed the Revenue's appeal and upheld the Order-in-Appeal dated 27th Apr'18. Consequently, the Tribunal confirmed the company's entitlement to a refund of accumulated CENVAT credit amounting to Rs 2,751 Lakhs (Rs 27.51 crore), along with applicable consequential interest, effectively concluding the ongoing tax dispute in favour of SPARC.
Filing of Application for Reclassification with Stock Exchanges
Others (Uncategorized) · 13 Aug 2026, 10:21 pm
SPARC Seeks Reclassification of Promoter Group to Public Category Sun Pharma Advanced Research Company (SPARC) has filed an application with stock exchanges on 13 Aug'26. The company is seeking approval to reclassify shareholders from the 'Promoter Group' category to the 'Public' category. This action follows previous intimations on 27 Jul'26 and 10 Aug'26 and is in accordance with SEBI's Listing Regulations. This change in shareholder classification could impact the company's ownership structure and increase the public float.
Outcome of 21st Annual General Meeting of Sun Pharma Advanced Research Company Limited held on August 10, 2026
Annual General Meeting · 11 Aug 2026, 1:17 am
Monitoring Agency Report for the Quarter ended June 30, 2026
Others (Uncategorized) · 10 Aug 2026, 8:26 pm
SPARC: Monitoring Report Confirms Utilization of Warrant Issue Proceeds For Q1 FY27, SPARC's monitoring agency, Acuité Ratings, confirmed no deviation in the use of proceeds from its preferential share warrant issue. Out of the INR 599.98 Cr issue size, INR 150.00 Cr was raised and fully utilized during the quarter for part repayment of a working capital loan from Kotak Mahindra Bank. The remaining INR 449.98 Cr earmarked for R&D (INR 300 Cr) and general purposes (INR 149.98 Cr) remains unutilized as no further subscriptions were received in the period.
Financial Results
Financial Result · 10 Aug 2026, 7:03 pm
SPARC Q1 FY27 Results: Net Loss Widens Amid Promoter Reclassification Approval SPARC's Board approved unaudited results for Q1 FY27 on 10 Aug'26. On a consolidated basis, the company reported a net loss of ₹2,078 lakhs for the quarter ending 30 Jun'26, widening from a loss of ₹5,187 lakhs YoY. Total revenue from operations stood at ₹3,992 lakhs, a significant increase from ₹964 lakhs in the prior year's quarter. The Board also approved the reclassification request for certain promoter group individuals to the "Public" category, subject to necessary approvals. Basic and diluted EPS stood at ₹(0.64).
Outcome of the Board Meeting
Outcome · 10 Aug 2026, 6:58 pm
Sun Pharma Advanced Research Company Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 3,992 (+314.1% YoY | -97.8% QoQ) ■ EBITDA: -3,400 (+34.7% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -85.2 (+45508 bps YoY | Profit to Loss QoQ) ■ PAT: -2,076 (+60.0% YoY | Profit to Loss QoQ) ■ EPS (INR): -0.64 (+60.0% YoY | Profit to Loss QoQ)
Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve unaudited ....
Intimation · 10 Aug 2026, 5:30 am
SPARC Board Meeting Scheduled for August 10 to Approve Q1 Results Sun Pharma Advanced Research Company (SPARC) has scheduled a Board of Directors meeting for Mon, Aug 10, '26. The agenda includes the consideration and approval of the unaudited standalone and consolidated financial results for the quarter ended Jun 30, '26. In connection with this, the trading window for designated persons has been closed from Jul 01, '26 and will reopen 48 hours after the financial results are declared to the stock exchanges.
Intimation for Receipt of Request for Reclassification of Shareholder Category
Others (Uncategorized) · 27 Jul 2026, 11:56 pm
SPARC: Promoter Group Members Seek Reclassification to Public Shareholders Sun Pharma Advanced Research Company (SPARC) received requests on 27 Jul'26 from three promoter group members to reclassify their status to the 'Public' category. The shareholders are Sudhir Vrundavandas Valia (0.57%), Raksha Sudhir Valia (1.28%), and Krishna Vrundavandas Valia. Collectively, they hold 59,79,182 shares, representing a 1.85% stake in the company. The company's Board of Directors will now consider these requests in accordance with SEBI regulations, with final approval pending the completion of the prescribed process.
Business Responsibility and Sustainability Report for FY 26
Others (Uncategorized) · 17 Jul 2026, 2:27 am
SPARC Submits FY26 Business Responsibility and Sustainability Report Sun Pharma Advanced Research Company (SPARC) filed its Business Responsibility and Sustainability Report for FY26 on 16 Jul'26. The company reported a total employee count of 466, with women comprising 21% of the workforce and 33% of the Board. The permanent employee turnover rate increased to 23% from 17% in FY25. For FY26, the company recorded total energy consumption of 18,772 GJ and total GHG emissions of 3,135 metric tonnes of CO2 equivalent. The company states it incurred no CSR expenditure due to losses in preceding years.
Notice of 21st Annual General Meeting along with the Annual Report for FY 26
Annual General Meeting · 17 Jul 2026, 2:23 am
Annual Report 2025-26 and the Notice of 21st Annual General Meeting
Others (Uncategorized) · 17 Jul 2026, 2:19 am
Intimation for change in Director
Change in Management · 13 Jul 2026, 11:16 pm
SPARC Appoints Anil Raghavan as MD & CEO Sun Pharma Advanced Research Company (SPARC) announced a key leadership transition. Mr. Anil Raghavan, the current CEO, will be appointed as Managing Director and CEO, effective 11 Aug'26. This follows the retirement of Director Dr. Rajamannar Thennati on 10 Aug'26 upon term completion. The appointment is subject to shareholder approval at the upcoming Annual General Meeting. Mr. Raghavan has prior experience with firms including Arthur Andersen and KPMG. This move solidifies leadership continuity as the company executes its strategic vision.
21st Annual General Meeting of the Company
Annual General Meeting · 06 Jul 2026, 6:13 pm
Intimation regarding Change in Senior Management Team of the Company
Change in Management · 27 Jun 2026, 12:11 am
SPARC Announces Key Senior Management Changes Sun Pharma Advanced Research Company announced senior management changes effective Jun 30, '26. Chief Operating Officer Dr. Nitin Dharmadhikari and Functional Head – HR & Administration Ms. Shanta Gupta will retire. Mr. Prasanna Deshmukh has been appointed as the new Functional Head – HR & Administration, effective Jul 01, '26. Mr. Deshmukh joins from Sun Pharmaceutical Industries Ltd., where he was HR Business Partner for Global Quality and Compliance since May '23, bringing experience from Marico Ltd. and Crompton Ltd.
Termination of License Agreement with CMS Bridging DMCC
Others (Uncategorized) · 26 Jun 2026, 12:09 am
SPARC Terminates License Agreement with CMS Bridging DMCC Sun Pharma Advanced Research Company (SPARC) announced the mutual termination of its license agreement with CMS Bridging DMCC, effective 25 Jun'26. The original agreement, dated 05 Nov'19, was for the development and commercialization of multiple products, including Xelpros and Elepsia, in Mainland China, Hong Kong, Macao, and Taiwan. SPARC has stated that the termination will have no material impact on its financial position, operations, or other activities. The parties involved are not related to any promoter or promoter group.
Statutory Auditors Certificate in terms of Regulation 169(5) of SEBI ICDRA Regualations, 2018
Others (Uncategorized) · 26 May 2026, 2:25 am
SPARC Receives Rs. 150cr for Preferential Warrant Allotment to Promoter Group Sun Pharma Advanced Research Company (SPARC) has completed a preferential allotment of 3,85,10,000 convertible warrants to Shanghvi Finance Private Limited, a promoter group entity. The warrants were issued at Rs. 155.80 each. On 19th May'26, the company received the initial application money of Rs. 149.99cr, representing 25% of the total issue consideration. Each warrant is convertible into one equity share. The statutory auditor, S R B C & Co LLP, has certified the receipt of funds in compliance with SEBI ICDR regulations.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 20 May 2026, 10:48 pm
SPARC: Promoter Group Acquires Warrants Worth ~₹600 Crore Promoter group entity Shanghvi Finance Private Limited has acquired 38.51 million convertible warrants in SPARC via preferential allotment on 19 May’26. The warrants are convertible into equity shares at ₹155.80 each, aggregating to an investment of ~₹600 crore. Upon full conversion, this will represent 10.61% of the expanded equity capital. Consequently, the total promoter and promoter group holding in SPARC will increase from 65.67% to a potential 69.31% on a fully diluted basis. The conversion can be exercised within 18 months.
Update on PDP-716 NDA
Others (Uncategorized) · 20 May 2026, 12:17 am
SPARC Partner Receives FDA Complete Response Letter for PDP-716 NDA Sun Pharma Advanced Research Company's (SPARC) licensing partner, Ocuvex Therapeutics Inc., received a Complete Response Letter (CRL) from the U.S. FDA on 19 May'26 for the PDP-716 New Drug Application (NDA). The CRL was issued due to inspection findings at the finished product manufacturing facility. Importantly, the FDA did not raise any other issues concerning the PDP-716 NDA, indicating potential resolution upon addressing the manufacturing concerns. This development introduces a delay in the potential approval and commercialization timeline for the drug.
Allotment of 3,85,10,000 warrants pursuant to Preferential Issue
Others (Uncategorized) · 19 May 2026, 6:12 pm
SPARC Allots 3.85 Crore Warrants to Shanghvi Finance via Preferential Issue On 19 May'26, Sun Pharma Advanced Research Company's committee approved the preferential allotment of 3.85 crore warrants to Shanghvi Finance Private Limited at an issue price of INR 155.80 per warrant. The company has received INR 150 crore, equivalent to 25% of the total issue price. Each warrant is convertible into one fully paid-up equity share of INR 1 face value. While the current paid-up capital is unchanged, it will increase upon the conversion of these warrants.